<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001160</url>
  </required_header>
  <id_info>
    <org_study_id>770096</org_study_id>
    <secondary_id>77-DK-0096</secondary_id>
    <nct_id>NCT00001160</nct_id>
  </id_info>
  <brief_title>Studies on Tumors of the Thyroid</brief_title>
  <official_title>Studies on Thyroid Nodules and Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in this study will be patients diagnosed with or suspected to have a thyroid
      nodule or thyroid cancer.

      The main purpose of this study is to further understand the methods for the diagnosis and
      treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the
      context of standard medical care that is offered to all patients with thyroid nodules or
      thyroid cancer. Other tests are performed for research purposes. In addition, blood and
      tissue samples will be taken for research and genetic studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate methods for preoperative diagnosis and therapy of
      differentiated and medullary thyroid cancer and to screen patients for participation in other
      protocols. Study subjects will include adults and children with thyroid nodules or cancer
      requiring diagnostic fine needle aspiration biopsy, surgery, radioiodine scanning or therapy
      for persistent or recurrent disease.

      In this natural history protocol, the use of methods for follow-up of patients using
      radiopharmaceutical tracers such as (131)I, (123)I, (99)mTc-Sestamibi, (111)Inpentetreotide
      and 18-FDG PET administered according to standard clinical practice indications, and
      68Gallium-DOTATATE (Octreotate)-administered per research protocol as indicated. All
      radionuclides will be administered according to standard clinical practice indications and
      published guidelines. The limitations and significance of serum thyroglobulin (Tg)
      measurement for diagnosing tumor recurrence will be assessed. The study will permit a
      continued evaluation of the risk/benefit ratio of already established methods of
      administering (131)I therapy including the impact of pre-treatment dosimetric calculations
      and administration of lithium (a well established, yet not widely used, adjuvant to (131)I
      treatment), especially in selected cases of thyroid cancer in which high-dose (greater than
      150mCi) (131)I therapy is clinically indicated.

      Under this protocol, samples of FNAB, benign nodules and cancer tissue specimens, blood
      samples for research studies will be collected to assess new immunohistochemical and
      molecular markers, and other techniques to characterize tumors for correlation with
      diagnosis, response to therapy and prognosis. Blood and urine specimens will be collected for
      future clinical and research studies in both the hypothyroid and euthyroid state. Coded
      clinical data will be entered in the National Thyroid Cancer Registry in selected patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 1977</start_date>
  <completion_date type="Anticipated">December 31, 2040</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2040</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of thyroid cancer</measure>
    <time_frame>annually</time_frame>
    <description>via blood draws, CT scans, physical examinations.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">99999</enrollment>
  <condition>Hurthle Cell Thyroid Cancer</condition>
  <condition>Tall Cell Variant Thyroid Cancer</condition>
  <condition>Follicular Thyroid Cancer</condition>
  <condition>Thyroid Cancer</condition>
  <condition>Papillary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>18-FDG PET/CT Scan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performed once using FDA-approved 18-FDGradiopharmaceutical tracer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68 Gallium Dotatate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68GA-DOTATATE administered via intravenously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT Scan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CT scan (neck, chest, abdomen, pelvis) performedonce using FDAapproved I-131radiopharmaceuticaltracer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI Scan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRI Scan (brain &amp;amp; bones) performed once if clinicallyindicated; MRI scan (liver) performed once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68-Gallium-DOTATATE</intervention_name>
    <description>68GA-DOTATATE will be administered via intravenously once for the research 68-Gallium-DOTATATE PET/CT scan.</description>
    <arm_group_label>68 Gallium Dotatate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT Scan</intervention_name>
    <description>CT scan (neck, chest, abdomen, pelvis) performed once using FDA approved I-131radiopharmaceutical tracer.</description>
    <arm_group_label>68 Gallium Dotatate</arm_group_label>
    <arm_group_label>CT Scan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI scan</intervention_name>
    <description>MRI Scan (brain &amp;amp; bones) performed once if clinically indicated; MRI scan (liver) performed once.</description>
    <arm_group_label>MRI Scan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18-FDG PET/CT scan</intervention_name>
    <description>Performed once using FDA-approved 18-FDG radiopharmaceutical tracer.</description>
    <arm_group_label>18-FDG PET/CT Scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Adults and children with known or suspected thyroid neoplasm will be considered for
        participation.

          1. Patients with thyroid nodules requiring evaluation and possible biopsy

          2. Patients with recent diagnosis of thyroid cancer requiring consultation and counseling
             about therapeutic options

          3. Patients with established thyroid cancer requiring specialized studies such as (131)I
             dosimetry

          4. Enrollment of high risk, non-iodine avid, inoperable thyroid cancer for standard
             treatment of screening for eligibility for other specific thyroid cancer protocols.

        EXCLUSION CRITERIA:

        1. Serious underlying medical conditions that restrict diagnostic testing or therapy such
        as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Klubo-Gwiezdzinska, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig S Cochran, R.N.</last_name>
    <phone>(301) 402-1880</phone>
    <email>craigc@bdg10.niddk.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanna Klubo-Gwiezdzinska, M.D.</last_name>
    <phone>(301) 496-5052</phone>
    <email>joanna.klubo-gwiezdzinska@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_1977-DK-0096.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Klubo-Gwiezdzinska J, Yang L, Merkel R, Patel D, Nilubol N, Merino MJ, Skarulis M, Sadowski SM, Kebebew E. Results of Screening in Familial Non-Medullary Thyroid Cancer. Thyroid. 2017 Aug;27(8):1017-1024. doi: 10.1089/thy.2016.0668. Epub 2017 Jul 19.</citation>
    <PMID>28657510</PMID>
  </reference>
  <reference>
    <citation>El Lakis M, Giannakou A, Nockel PJ, Wiseman D, Gara SK, Patel D, Sater ZA, Kushchayeva YY, Klubo-Gwiezdzinska J, Nilubol N, Merino MJ, Kebebew E. Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment. Surgery. 2019 Jan;165(1):50-57. doi: 10.1016/j.surg.2018.05.075. Epub 2018 Oct 14.</citation>
    <PMID>30327187</PMID>
  </reference>
  <reference>
    <citation>Luo H, Tobey A, Auh S, Cochran C, Zemskova M, Reynolds J, Lima C, Burman K, Wartofsky L, Skarulis M, Kebebew E, Klubo-Gwiezdzinska J. The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy. Clin Endocrinol (Oxf). 2018 Oct;89(4):481-488. doi: 10.1111/cen.13806. Epub 2018 Aug 13.</citation>
    <PMID>29972703</PMID>
  </reference>
  <verification_date>July 16, 2020</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid Fine Needle Biopsy</keyword>
  <keyword>Radioiodine</keyword>
  <keyword>Dosimetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Adenocarcinoma, Follicular</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

